Biocon Limited has informed the Exchange about press release dated 19-May-2022 titled "Biocon Biologics and Viatris Launch Abevmy�� (bBevacizumab), Their Third Oncology Biosimilar, in Canada"
Biocon Limited has informed the Exchange about press release dated 19-May-2022 titled "Biocon Biologics and Viatris Launch Abevmy�� (bBevacizumab), Their Third Oncology Biosimilar, in Canada"